Phase 2
Completed N=29
Effectiveness of Antibiotic Treatment for Reducing Binge Eating and Improving Digestive Function in Bulimia Nervosa
Bulimia Nervosa · eating disorders
Source: ClinicalTrials.gov NCT00304187 ↗
Enrolled (actual)
29
Serious AEs
0.0%
Results posted
Jul 2013
Primary outcomePrimary: Binge Frequency — 10.4; 11.3 Binge Episodes/Week — p=<.05
Summary
This study will determine the effectiveness of the antibiotic erythromycin in enhancing gastrointestinal function and decreasing the frequency of binge eating in people with bulimia nervosa.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Binge Frequency |
10.4; 11.3 | <.05 sig |
| PRIMARY Percent of Meal Remaining/Minute |
-.339; -.177 | — |
Eligibility Criteria
Inclusion Criteria
- Meets criteria for bulimia nervosa
- Duration of illness is greater than 1 year
- Self-induces vomiting
- Weighs 80%-120 % of ideal weight
Exclusion Criteria
- Significant medical illness
- Current or lifetime history of schizophrenia, bipolar disorder, or other psychotic disorder, as defined by American Psychiatric Association criteria
- Moderate to severe depression, as defined by a score greater than 18 on the Hamilton Depression Scales
- Current diagnosis of organic mental disorder, factitious disorder, or malingering
- History of a personality disorder (e.g., schizotypal, borderline, or antisocial) that might interfere with assessment or compliance with the study procedures
- At risk for suicide
- Current psychotropic medications and current medications that affect GI function or that inhibit or induce cytochrome three A gene expression
- Currently pregnant, lactating, or planning to become pregnant
- Drug or alcohol abuse within the 3 months prior to study entry
- Abnormal EKG at baseline or 1 week following each upward dosage adjustment
- Anemia
- Known intolerance to erythromycin, or related antibiotics
- Abnormal results on liver function tests
- Electrolyte abnormalities
Data sourced from ClinicalTrials.gov (NCT00304187). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.